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Tumors frequently arise as a result of an acquired genomic instability and the subsequent
evolution of neoplastic populations with variable genomes. A barrier to the study of the
somatic genetics of human solid tumors in vivo is the presence of admixtures of non-
neoplastic cells with normal genomes in patient samples.These can obscure the presence
of somatic aberrations including mutations, homozygous deletions, and breakpoints in
biopsies of interest. Furthermore, clinical samples frequently contain multiple neoplastic
populations that cannot be distinguished by morphology. Consequently, it is difficult to
determine whether mutations detected in a sample of interest are concurrent in a sin-
gle clonal population or if they occur in distinct cell populations in the same sample. The
advent of targeted therapies increases the selection for preexisting populations. However
the asymmetric distribution of therapeutic targets in clonal populations provides a mecha-
nism for the rapid evolution of resistant disease. Thus, there is a need to not only isolate
tumor from normal cells, but to also enrich distinct populations of clonal neoplastic cells in
order to apply genome technologies to identify clinically relevant genomic aberrations that
drive disease in patients in vivo. To address this we have applied single and multiparame-
ter DNA content based flow assays to the study of solid tumors. Our work has identified
examples of clonal resistance to effective therapies. This includes androgen withdrawal
in advanced prostate cancer. In addition we demonstrate examples of co-existing clonal
populations with highly aberrant genomes and ploidies in a wide variety of solid tumors.
We propose that clonal analysis of tumors, based on flow cytometry and high resolution
genome analyses of purified neoplastic populations, provides a unique approach to the
study of therapeutic responses and the evolution of resistance.
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INTRODUCTION
Nowell (1976) proposed that tumors arose as a result of an
acquired genomic instability and the subsequent selection and
evolution of clonal populations of neoplastic cells with unique
patterns of aberrations. Consequently, each patient’s cancer may
evolve and become dependent on distinct sets of selected aber-
rations during its clinical history. This clonal evolution model
was based on studies primarily of liquid tumors using low reso-
lution cytogenetics that showed uniform karyotypes of all cells in
individual patient samples, biochemical assays, and allele-specific
chromosome X expression of glucose-6-phosphate isoenzymes
in all cells of a variety of neoplasms in heterozygous women,
and immunology studies of homogeneous immuno-globulins in
plasma cell tumors. Furthermore this model predicted that clonal
behavior would mediate emergence of resistance even after an ini-
tial clinically significant response. Advances in genome technolo-
gies, notably oligonucleotide-based arrays and next generation
sequencing (NGS) platforms, have greatly increased the resolu-
tion potential for studying the basis of therapeutic resistance in
human cancers. A number of recent NGS studies have proposed
evolutionary models of tumor development and progression based
on heterogeneous patterns of mutations in primary and metastatic
lesions (Gerlinger et al., 2012). These advances in technology and
cancer genomics provide a rich opportunity to study the basis of
therapeutic responses and the evolution of resistance.
A fundamental hypothesis in cancer biology is that the genes
and cellular pathways deregulated by those selected events in
each tumor genome represent enriched candidates for developing
diagnostic markers and therapeutic targets. However, the cellular
heterogeneity of clinical samples and the genetic diversity of cancer
genomes are barriers to the translation of genomics for improved
patient care. The presence of admixtures of non-neoplastic cells in
patient samples can obscure the detection of somatic aberrations
including mutations, homozygous deletions, and breakpoints in
biopsies of interest. Furthermore, clinical samples frequently con-
tain multiple neoplastic populations that cannot be distinguished
by morphology based methods (Rabinovitch et al., 1999; Maley
et al., 2006). Consequently, it is difficult to determine whether
mutations and aberrations in a sample of interest are concur-
rent in a single tumor population or if they occur in distinct cell
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populations in the same sample. Thus, there is a need to not only
isolate tumor from normal cells, but to also enrich distinct popu-
lations of clonal neoplastic cells in order to study cancer genomes
in patients in vivo.
Cancer genome studies have relied primarily on two main
approaches for selecting and preparing samples for analyses. The
first is to pre select biopsies that exceed an arbitrary threshold
for tumor cell content and necrosis based on histological meth-
ods such as H&E staining (Cancer Genome Atlas Research, 2011;
Guichard et al., 2012; Nik-Zainal et al., 2012). However many
samples fail the criteria; this is especially true for tumors aris-
ing in solid tissues where a high degree of tissue heterogeneity,
with varied admixtures of reactive stroma, inflammatory cells, and
necrosis in immediate contact with tumor cells, is a very common
feature. Laser capture microdissection (LCM) can enrich tumor
cell content prior to analysis. However LCM is limited in abil-
ity to objectively distinguish multiple clonal populations in single
biopsies and in processing throughput for heavily admixed sam-
ples. The second approach is to passage biopsies either in tissue
culture or in mouse xenografts (Jones et al., 2008). These meth-
ods apply a selective pressure on the complex mixtures of cells
and clones present in a patient sample. Furthermore they can
be time consuming, labor intensive, and cannot be efficiently
applied in most clinical settings. Consequently the number of
samples that can be successfully passaged varies from site to
site, and the biological complexity and clinical context of the
patient sample may not be reflected in the final processed sample.
More recently, studies have used mixtures of tumor and normal
cells to estimate thresholds for the detection of somatic muta-
tions to compensate for the complex composition and cellular
admixtures of clinical samples (Biankin et al., 2012). However
these methods do not fully account for clonal heterogeneity, are
dependent on depth of reads across each genome of interest, and
require additional processing and filtering of increasingly complex
data sets.
A major objective for cancer genome studies is to distinguish
“driver”aberrations that target clinically significant signaling path-
ways from “passenger” aberrations that arise as a result of the
biological background in genomically unstable tumors. A com-
mon approach for identifying clinically relevant cancer genome
aberrations is to characterize lesions, including any loss or any
gain for each chromosome, occurring at rates that are statisti-
cally significant in samples of interest (Aguirre et al., 2004; Weir
et al., 2007; Chen et al., 2008; Kimmelman et al., 2008; Bredel
et al., 2009; Liu et al., 2009). Single copy losses and gains occur
as part of the random events associated with genomic instabil-
ity present in tumor genomes. Thus many cancer genome studies
determine a statistical threshold based on the background rates
of losses and gains for detecting selected copy number changes.
However this requires relatively large numbers of patient sam-
ples to account for the genomic instability and the patient spe-
cific variations typically present in cancer genomes. Furthermore
recent NGS based studies have shown that the genomic landscapes
of most solid tumors contain a wide variety of low prevalent
mutations (McKenna et al., 2010; Biankin et al., 2012). Thus
a fundamental challenge in the translation of cancer genomes
for improved patient outcomes is the identification of selected
genomic aberrations including somatic mutations that target
clinically relevant signaling pathways in patients in vivo.
In order to address the complexity and heterogeneity of clinical
samples we have applied highly quantitative DNA content based
flow cytometry assays to identify and subsequently sort distinct
fractions of tumor and non-tumor populations in each sample
of interest (Ruiz et al., 2011; Liu et al., 2012). Flow cytometry
cell sorters can select and objectively measure individual particles
such as cells or nuclei using desired features defined by fluorescent
and light scattering parameters in a flow stream. Once identified
desired subpopulations can be deflected in the stream by an electric
field and collected as pure objectively defined populations. Recent
advances in this technology combine high efficiency flow rates with
the detection of relatively rare events in dilute samples enabling
the application of flow cytometry to clinical biopsies from clini-
cal tissues (Ibrahim and van den Engh, 2003, 2008). For example,
there are well established DNA staining based methods for isolat-
ing nuclei of aneuploid and diploid neoplastic populations from
solid tumor samples (Rabinovitch, 1994; Glogovac et al., 1996).
Tumor populations can be objectively and quantitatively purified
to greater than 95% purity for molecular analyses even in heav-
ily admixed clinical samples. In addition these methods can be
combined with either proliferation markers such as Ki67 or tissue
specific markers such as cytokeratins to purify distinct popula-
tions of diploid neoplastic cells from samples of interest (Prevo
et al., 1999; Loo et al., 2004; Galipeau et al., 2007). Flow sort-
ing has been successfully used for a variety of human neoplasias
including breast, esophageal, lung, and colon carcinomas (Lofberg
et al., 1992; Tanaka et al., 1995; Takanishi et al., 1996; Barletta et al.,
1998; Loo et al., 2004; Lai et al., 2007). Recently we have developed
methodologies that enable the study of flow sorted clinical samples
with high definition whole genome assays, including oligonu-
cleotide array based comparative genomic hybridization (aCGH)
and NGS (Ruiz et al., 2011; Holley et al., 2012). The application
of clonal analysis, based on whole exome and genome measure-
ments of purified populations from clinical samples, provides a
highly favorable approach to studying therapeutic responses and
advancing more effective targeted therapies.
MATERIALS AND METHODS
Pancreatic ductal adenocarcinoma (PDA) samples were obtained
under a WIRB protocol (20040832) for an NIH funded bio speci-
men repository (NCI P01 Grant CA109552) and two AACR/Stand
up to Cancer (SU2C) sponsored clinical trials 20206-001 and 2026-
003. Additional PDA samples as well as prostate carcinoma and
ovarian carcinoma samples were obtained with approved consent
of the Ethics Committee of Basel (252/08, 302/09). The melanoma
tissue samples analyzed in this study were obtained under the
Institutional Review Board approved protocols at Mayo Clinic.
In all cases the tissues were acquired and the study was con-
ducted according to Good Clinical Practice and the Declaration
of Helsinki Principles with informed consent from each patient.
FRESH TISSUE SAMPLE PREPARATION AND FLOW SORTING
Wherever possible clinical samples are collected in liquid nitrogen
and stored at−80˚C. These include needle biopsies (e.g., 18 g), sur-
gically resected tissues, pleural effusions, and core needle biopsies
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from various organ sites. Alternatively samples may be collected
in small aliquots of tissue culture media supplemented with 10%
DMSO and held on wet ice. These can then be transferred to−80˚C
for long term storage. The use of media with DMSO provides fur-
ther tissue preservation in those cases where multiple sampling of
the tissue involves cycles of freeze thawing. Prior to sorting each
biopsy is quickly thawed on ice then minced in the presence of NST
buffer and DAPI according to published protocols (Rabinovitch
et al., 2001; Maley et al., 2006; Galipeau et al., 2007). Nuclei are
mechanically disaggregated then filtered through a 40-µm mesh
prior to flow sorting with an Influx cytometer (Becton-Dickinson,
San Jose, CA, USA) with ultraviolet excitation and DAPI emission
collected at >450 nm. DNA content and cell cycle are analyzed
using the software program MultiCycle (Phoenix Flow Systems,
San Diego, CA, USA).
FORMALIN FIXED PARAFFIN EMBEDDED SAMPLE PREPARATION AND
FLOW SORTING
Formalin fixed paraffin embedded (FFPE) samples are fixed in for-
malin at the time of collection then stored according to routine
pathology methods. Prior to sorting excess paraffin is removed
with a scalpel from either side of 40–60µm scrolls to reduce
accumulation of debris during the sorting process. Each scroll is
collected into individual microcentrifuge tubes then washed three
times with 1 ml Xylene for 5 min to remove remaining paraffin.
Each sample is rehydrated in sequential ethanol washes (100%
5 min ×2, then 95, 70, 50, and 30% ethanol) and washed two
times in 1 ml of 1 mM EDTA pH 8.0. A 1-ml aliquot of 1 mM
EDTA pH 8.0 is added to the samples and incubated at 95˚C for
80 min to facilitate the removal of protein cross-links present in
FFPE tissue. Samples are then cooled to room temperature for
≥5 min, followed by addition of 300µl PBS pH 7.4 and gentle
centrifugation for 2 min at 3.6× g. The supernatant is carefully
removed and the pellet washed three times with 1 ml PBS pH
7.4/0.5 mM CaCl2 to remove EDTA. Each sample is then digested
overnight (6–17 h) in 1 ml of a freshly prepared enzymatic cocktail
containing 50 units/ml of collagenase type 3, 80 units/ml of puri-
fied collagenase, and 100 units/ml of hyaluronidase in PBS pH
7.4/0.5 mM CaCl2 buffer. Each enzyme is rehydrated with PBS pH
7.4/0.5 mM CaCl2 buffer then stored at−20˚C immediately prior
to addition to the cocktail mixture. Following overnight diges-
tion 500µl NST is added to each sample to facilitate pelleting.
Samples are then centrifuged for 5 min at 3000× g, after which
pellets are resuspended in 750µl of NST/10% fetal bovine serum
and then passed through a 25-G needle 10–20 times. The sam-
ples are filtered through a 35µm mesh and collected into a 5 ml
Polypropylene round bottom tube. The mesh is rinsed with an
additional 750µl of NST/10% fetal bovine serum and placed on
ice while processing remaining samples. The total volume in the
tube for each sample is approximately 1.5 ml. An equal volume of
20µg/ml DAPI is then added to each tube to achieve a final con-
centration of 10µg/ml DAPI prior to flow sorting with an Influx
cytometer with ultraviolet excitation (Becton-Dickinson, San Jose,
CA, USA). The optimal settings for sorting FFPE samples with the
Influx sorter are as follows: drop formation is achieved with piezo
amplitude of 6–10 V and a drop frequency of 30 kHz. The sort
mode is set to purity yield with a drop delay of 31.5–32. Sheath
fluid pressure is typically 17–18 psi with a 100µm nozzle. For sin-
gle parameter DNA content assays DAPI emission is collected at
>450 nm. In each sorting experiment we used one or more 50µm
FFPE scrolls to obtain sufficient numbers of intact tumor nuclei
for subsequent molecular assays. DNA content and cell cycle are
then analyzed using the software program MultiCycle (Phoenix
Flow Systems, San Diego, CA, USA).
Gating based on DNA content provides a robust quantitative
measure for identifying and sorting tumor populations from sam-
ples of interest. The ploidy and the relative distribution of each
population present in a biopsy can be recovered by fitting the
G0/G1 and G2/M peaks as Gaussian curves and the S phase distri-
bution as a Gaussian broadening distribution. The DNA content
histograms from tumor tissue are frequently suboptimal (broad
c.v’s, high debris and aggregation) and often complex (multi-
ple overlapping peaks and cell cycles) with frequent skewing and
non-Gaussian peak shapes. This is even truer for FFPE specimens
that often contain higher levels of damaged or fragmented nuclei
(debris) resulting in events usually most visible to the left of the
diploid G1 peak and that fall rapidly to baseline. For reproducible
phase measurements we typically acquire 10,000 events. However
if a substantial proportion of events are from debris or aggre-
gates, the total number of events acquired must be correspondingly
higher in order to assure the required minimum number of intact
single nuclei for accurate curve fitting. Despite these challenges dis-
tinct populations can be efficiently sorted from routinely prepared
FFPE samples.
DNA EXTRACTION
The genomic DNA from sorted nuclei is extracted using an
amended protocol from QIAamp® DNA Micro Kit from Qiagen
(Valencia, CA, USA). Briefly each sorted sample is resuspended
in 180µl buffer ATL and 20µl proteinase K then incubated for
3 h at 56˚C for complete lysis. Samples are bound and washed
according to QIAamp® DNA Micro Kit instructions, eluted into
50µl of H20, then precipitated overnight with 5µl 3 M sodium
acetate and 180µl 100% EtOH. Each sample is then centrifuged
for 30 min at 20,000× g, washed in 1 ml of 70% EtOH for 30 min
at 20,000× g. The samples are carefully decanted and the DNA
pellet was dried by speed vacuum then resuspended in a small vol-
ume (e.g., 10–50µl) of H2O for final concentrations suitable for
accurate quantification.
DNA AMPLIFICATION
To make efficient use of sorted clinical samples we have optimized
whole genome amplification methods to generate DNA templates
suitable for whole genome and exome analyses. Sorted populations
from fresh frozen samples can be amplified with highly processive
enzymes such as phi29 that require intact genomic DNA as starting
material. Extracted fresh frozen sourced genomic DNA is ampli-
fied using the Illustra GenomiPhi V2 Amplification kit from GE
Healthcare Bio-sciences, Corp. (Piscataway, NJ, USA) according
to our published protocols (Ruiz et al., 2011). Typically we use
>50 ng genomic DNA from each sorted population as input to
ensure linear amplification across the genome.
For FFPE samples the DNA templates are not suitable for ampli-
fication protocols with highly processive polymerases. Thus we
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validated an alternative method based on single primer based
amplification of size selected double strand DNA input (Hol-
ley et al., 2012). Genomic DNAs from sorted FFPE samples are
amplified using Ovation® WGA FFPE System from NuGEN® Tech-
nologies (San Carlos, CA, USA). DNA is processed in accordance
with Ovation® WGA FFPE standard SPIA protocol with an alter-
nate T7 endonuclease fragmentation step. These protocols require
input from 50,000 sorted nuclei as starting material to ensure
a linear amplification. Resulting amplified products are either
used as template for aCGH analysis or processed with the Nugen
Encore ds-DNA module according to the supplier’s instructions
in order to generate double-stranded (ds) end-repaired DNA as
input for library suitable for NGS. In all cases A 50–100 ng aliquot
of pooled 46,XX DNA (Promega, Madison, WI, USA) is amplified
with the matching amplification protocol to generate a suitable
reference for each aCGH experiment using amplified DNA tem-
plates. The quality of each amplification product is assessed by gel
electrophoresis prior to downstream analysis.
aCGH ANALYSIS
Fresh frozen phi29 amplified and FFPE non-amplified DNAs are
treated with DNAse 1 prior to Klenow-based labeling. High mol-
ecular weight phi29 templates are digested for 30 min while the
smaller fragmented FFPE samples are digested for only 1 min. In
each case 1µl of 10× DNase 1 reaction buffer and 2µl of DNase
1 dilution buffer are added to 7µl of DNA sample and incubated
at room temperature then transferred to 70˚C for 30 min to deac-
tivate DNase 1. In contrast the amplified FFPE sourced DNAs do
not require DNase 1 treatment prior to Klenow-based labeling.
In all cases sample and reference templates are labeled with Cy-5
dUTP and Cy-3 dUTP respectively using a BioPrime labeling kit
(Invitrogen, Carlsbad, CA, USA) according to our published pro-
tocols (Ruiz et al., 2011). All labeling reactions are assessed using
a Nanodrop assay (Nanodrop, Wilmington, DE, USA) prior to
mixing and hybridization to 400 k CGH arrays (Agilent Technolo-
gies, Santa Clara, CA, USA) for 40 h in a rotating 65˚C oven. All
microarray slides are scanned using an Agilent 2565C DNA scan-
ner and the images are analyzed with Agilent Feature Extraction
version 10.7 using default settings. The aCGH data are assessed
with a series of QC metrics then analyzed using an aberration
detection algorithm (ADM2; Lipson et al., 2006). The latter iden-
tifies all aberrant intervals in a given sample with consistently high
or low log ratios based on the statistical score derived from the
average normalized log ratios of all probes in the genomic interval
multiplied by the square root of the number of these probes. This
score represents the deviation of the average of the normalized log
ratios from its expected value of zero and is proportional to the
height h (absolute average log ratio) of the genomic interval, and
to the square root of the number of probes in the interval.
EXOME LIBRARY PREPARATION
A total of 3µg of high-quality DNA template with a 260/280 ratio
between 1.8 and 2.1 is fragmented to a target size of 150–200
base pairs on the Covaris E210 system. Fragmentation is veri-
fied on a 2% TAE gel and fragmented samples are end-repaired
using New England Biolab’s NEB Next kit (Ipswich, MA, USA).
Repaired samples are adenylated at the 3′ end using the NEBNext
kit, and Illumina indexed adapters are next ligated onto A-tailed
products. Samples are next PCR amplified using Herculase II
polymerase and purified. Samples are then run on an Agilent
Bioanalyzer to verify amplification and to quantify samples. Sam-
ples are adjusted to 147 ng/µL for 24 h hybridization to exonic
RNA probes using Agilent’s SureSelect All Exon 50 Mb Plus kit,
which contains 561,823 probes targeting 202,124 exons. Captured
products are next selected for, purified, and PCR amplified. Final
libraries are verified and quantified using an Agilent Bioanalyzer.
PAIRED END NEXT GENERATION SEQUENCING
Libraries are denatured using 2 N NaOH and diluted with HT2
buffer (Illumina). One percent of denatured and diluted phiX
is spiked into each lane to allow for error rate reporting on the
HiSeq. Cluster generation is performed using Illumina’s cBot and
HiSeq Paired End Cluster Generation Kit. Flow cells are paired
end sequenced on Illumina’s HiSeq 2000 using Illumina’s HiSeq
Sequencing Kit. Raw sequencing data are converted to standard
FASTQ format using CASAVA pipeline with in-house custom
scripts1,2. FASTQC program is used for quality control and all
reads are trimmed to 90 high-quality base pairs. In order to gen-
erate at least 100 million pass filter reads for each exome library,
two lanes of a HiSeq 2000 flowcell are sequenced for each of the
FFPE and fresh frozen exomes. Data is aligned to hg18 assembly of
human genome using BWA sequence alignment software (version
0.5.9) and raw alignment BAM files are further processed for qual-
ity recalibration, duplicate removal, and local realignment using
a custom in-house pipeline based on Picard and GATK tools3 (Li
and Durbin, 2009; McKenna et al., 2010; DePristo et al., 2011). For
each sample, variants are called from BAM files using samtools and
varscan using a minimum coverage cut-off of 10, and only those
variants that are called by both algorithms are retained (Koboldt
et al., 2009; Li et al., 2009).
RESULTS
CLONAL ANALYSIS: SINGLE PARAMETER DNA CONTENT BASED FLOW
SORTING
Flow cytometry methods can discriminate distinct populations
in each biopsy of interest based on one or more features. The
basic principle for flow sorting is to interrogate single parti-
cles in suspension for desired parameters. These include ploidy
as defined by the mean DNA content, as well as differentiation
or cell lineage markers. Clonal populations in tumors can then
be distinguished by differences in ploidy, copy number aberra-
tions, mutations, or differentiation. For solid tumor samples tissue
are mechanically disaggregated and the nuclei suspended in the
presence of DAPI. The isolation of nuclei provides an efficient
mechanism to prepare single particle suspensions that can be
interrogated in a flow stream. A hallmark of many human can-
cers is the development of genomic instability and the evolution
of aneuploid tumor cell lineages. Thus for many solid tumors
DNA content assays can be very effective in identifying and subse-
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example we identified four distinct populations in a biopsy from a
PDA surgical resection (Figure 1). Each of these populations was
collected in our sorting assay then processed for whole genome
analysis. These included a genomically normal diploid popula-
tion as well as a small tumor aneuploid population. The ability
to collect four simultaneous streams in these assays optimizes the
use of each clinical sample and provides isogenic populations for
analysis.
TUMOR MARKERS AND THERAPEUTIC TARGETS
Pancreatic ductal adenocarcinoma is a highly lethal tumor type
that is difficult to molecularly characterize at the biopsy level
due to complex genomes and heterogeneous cellularity, as can-
cer cells represent on average only 25% of the cells within the
tumor (Seymour et al., 1994). Previous studies of PDA have relied
on tumor derived cell lines and xenografts to obtain samples for
genome studies (Jones et al., 2008). However these methods cre-
ate selective pressures on tumor cells, are typically labor intensive,
and require fresh tissues limiting their utility for patient based
studies. More recently, studies have used mixtures of tumor and
normal cells to estimate thresholds for the detection of somatic
mutations to compensate for the complex composition and cel-
lular admixtures of clinical PDA samples (Biankin et al., 2012).
In contrast we apply our flow sorting methods to clinical samples
and profile the genomes of each sorted population. These highly
purified clonal preparations are used for high definition genomic
analyses to determine the landscape of aberrations present in each
tumor. The ability to profile patient samples regardless of tumor
cell content provides an unbiased approach to the study of PDA
genomes.
A striking observation in our ongoing studies of PDA is the
unique nature of the genomes profiled from each patient. For
example a 3.7N aneuploid population representing <8.0% of
a PDA sample had a focal amplicon on 6p21 as the most sig-
nificant copy number gain in its genome (Figure 2). This high
level focal amplicon includes the VEGFA gene and the nucleoside
transporter gene SLC29A (ENT1) that regulates intracellular gem-
citabine levels. The presence of these co-amplified genes suggests
a clinical hypothesis that this tumor has a context of vulnera-
bility to therapy based on anti-angiogenic agents and would be
responsive to gemcitabine. In addition this same genome had a
focal homozygous deletion targeting JARID2, a regulator of his-
tone methyltransferase complexes during normal development.
A current hypothesis in our PDA clinical studies is that loss of
normal epigenetic regulation may make tumors responsive to
combination treatments that include hypomethylation agents such
as 5-azacytidine.
Single copy gains and losses can arise at high rates as a result of
the genomic instability that is a hallmark of many tumors. In con-
trast, events such as homozygous deletions and focal high level
amplifications typically require multiple independent genomic
events and thus can represent biologically selected events in can-
cer genomes that target known and putative tumor suppressor
genes and activated oncogenes. The identification of genes targeted
FIGURE 1 | Clonal profiling: flow sorting neoplastic cells from solid
tissue biopsies. (A) Biopsies are minced in the presence of DAPI then
mechanically disaggregated to create single nuclei suspensions. These are
then flow sorted in single or multiparameter assays. (B) Scatter plot,
displaying events during sorting, are used to generate histograms to identify
then subsequently sort populations of interest. Table displays quantitative
analysis of the four peaks (P1–P4) detected in a pancreatic adenocarcinoma
sample. (C) Each peak was sorted and collected into individual tubes. (D)
Genomic DNA from each purified population is extracted then processed for
assays of interest including whole genome and whole exome analyses.
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FIGURE 2 | Clonal analyses of pancreatic ductal adenocarcinoma
(PDA) biopsy P1026Z. (A) DAPI-based DNA content analysis detected
a 3.7N population representing 7.6% of the cellular content of the
biopsy. Only the 3.7N population showed homozygous deletions and
focal amplicons. (B) Chromosome 6 and (C) locus-specific views of the
JARID2A homozygous deletion and the VEGFA SLC29A1 amplicon in
the 3.7N PDA genome. Blue shade areas denote ADM2 aberrant
intervals.
by these selected events provides insights into signaling path-
ways that may drive the clinical behavior of individual tumors.
For example previous reports have identified somatic mutations
of NUMB in breast carcinoma and of PARK2 in GBM, colon,
and lung cancers (Colaluca et al., 2008; Veeriah et al., 2010). We
have identified homozygous deletions in both of these genes pro-
viding evidence that their tumor suppressor function extends to
PDA. The potential clinical significance of homozygous deletions
is highlighted by the prediction that complete loss of NUMB
results in increased Notch signaling which can be targeted by
gamma secretase inhibition or by blocking the Notch receptor
directly (Figure 3). These same genomic analyses have also iden-
tified homozygous deletions in a series of other known (e.g.,
SMAD2, SMAD3, JARID2) and putative (SMYD3, USP25) tumor
suppressor genes that are selectively disrupted in PDA genomes.
Given that many tumor suppressor genes targeted by homozy-
gous deletion have frequent sequence mutations the latter pro-
vide highly favorable candidates for resequencing and IHC based
assays.
The detection of the complete loss of genomic sequence is
highly sensitive to as little as 5% admixtures of non-tumor cells in
clinical samples (Zhao et al., 2004). This is consistent with recur-
ring observations that fewer aberrations can be detected in patient
samples in vivo than in passaged model systems (Jones et al., 2008;
Leary et al., 2008; Parsons et al., 2008). However a limitation in
many cancer genome studies is the inability to objectively dis-
criminate single copy losses from homozygous deletions and to
accurately map and determine high level amplification in cancer
genomes arising in individual patient samples. Thus copy number
data is typically reduced to reporting frequencies of any loss or
any gain for each chromosome in relatively large cohorts of sam-
ples. This further limits the translational potential of the genomic
study of cancers including those with variable complex genomes,
rare cancers, and biopsies with high admixtures of genomically
normal cells and insufficient tumor cell content (Aguirre et al.,
2004). Furthermore, histology-based methods cannot readily dis-
tinguish whether aberrations in a tumor are present in a sin-
gle cancer genome or if they are distributed in multiple clonal
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FIGURE 3 | Clinical significance of NUMB homozygous deletion in
pancreatic ductal adenocarcinoma (PDA) genome. (A) Homozygous
deletion of the Numb tumor suppressor gene in an aneuploid clone isolated
from a PDA sample. Shaded areas represent copy number aberrant regions
called by ADM2 algorithm. (B) Concept map of Numb and its interactions
with Notch and TP53 pathways.
populations. Consequently current approaches for the analyses of
cancer genomes are limited in their ability to determine the clinical
context of each patient’s tumor.
In order to further validate our clonal methods we have applied
those to our ongoing Stand Up to Cancer (SU2C) PDA clinical tri-
als. The first of these trials, 2026-001, involves molecular profiling
of patients with previously treated metastatic disease. For each of
the 35 patients in this trial one to three 18g needle biopsies from
a liver metastasis was available for analysis. These samples were
subsequently analyzed for a panel of IHC markers under CLIA
conditions to identify a clinically actionable target. As a correlative
samples of these same tissues were also processed for clonal analy-
sis using single parameter DNA content sorting and aCGH for each
sorted population. An example of these studies is a patient who had
previously been treated with 5-FU based therapy (Figure 4). Three
distinct populations were identified and subsequently sorted from
the liver metastasis biopsy. The genome of each sorted population
was then profiled by aCGH. The diploid and tetraploid fractions
were genomically normal by copy number analysis. In contrast
we detected a series of somatic genomic aberrations in the 3.1N
population. These included a focal gain at 18p11.32 that included
the thymidylate synthase (TYMS) locus whose protein product is
targeted by 5-FU based therapies. IHC revealed an increased level
of TYMS. This suggests that prior treatment resulted in amplifica-
tion of this region and increased protein levels and gave rise to the
therapeutic resistance that arose in this patient during treatment.
CLONAL HETEROGENEITY IN SINGLE BIOPSIES
Our ongoing clinical studies have provided a unique view of
clonal heterogeneity and show that clonal evolution can be dri-
ven by different biological events in patient samples. For example
the presence of distinct aneuploid populations with overlapping
copy number aberration profiles suggests a mitotic event con-
tributed to the heterogeneity of the tumor. In some of these
cases simultaneous ploidies acquire relatively subtle copy num-
ber differences in their genomes. Single parameter DNA content
sorting identified two distinct ploidies (3.2N and 2.7N) in a liver
metastasis that shared a series of genomic aberrations including
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FIGURE 4 | Clonal analysis of pancreatic ductal adenocarcinoma
(PDA) liver metastasis from SU2C clinical trial. (A) DNA content
flow sorting identified and purified three distinct peaks in the single
biopsy. (B) The 2.0N and 4.0N populations were genomically normal
while the 3.1N population had multiple copy number aberrations
throughout its genome. (C) Focal amplicon on 18p11.32 that included
the thymidylate synthase (TYMS) locus. Blue shade areas denote
ADM2 aberrant intervals.
focal amplification of FZD3 (8p21) and homozygous deletions
of MAP2K4 (17p12) and CDKN2A (9p21.3; Figure 5). In addi-
tion each of the clonal populations had a deletion with matching
boundaries on 21q. In the 3.2N genome the deletion was homozy-
gous as measured by a log2ratio value of <−3.0 for CGH probes
in the interval. In contrast the same interval was only partially
deleted in the 2.7N population. Given that the MAP2K4 and
CDKN2A deletions were homozygous in both populations these
data suggests that the distinct aneuploid populations evolved after
metastasizing to the liver and that the 3.2N clone acquired com-
plete loss of this region as a result of ongoing genomic instability.
The presence of these two distinct but highly related clonal pop-
ulations in a single liver metastasis highlights the ongoing nature
of evolution in PDA.
We have made similar observations of ongoing instability and
evolution in a wide variety of solid tumors including melanoma,
adrenal cortical carcinoma, breast cancer, hepatocellular carcino-
mas, and colon carcinoma. The significance of clonally diverging
events and their possible role in resistance to therapy and disease
progression is being followed in ongoing clinical trials. A fun-
damental hypothesis is that distinct clones will have differential
responses to selective therapies. A challenge for clinical trials and
advancing personalized therapies for patients with solid tumors
will be to objectively measure genomic lesions in one or more
genomes present in clinical samples of interest.
CLONAL HETEROGENEITY IN METACHRONOUS SAMPLES
A striking example of clonal heterogeneity is shown in an ovarian
carcinoma with biopsies from the primary tissue and a pleural
effusion sample acquired 1 year later. DNA content sorting iden-
tified two aneuploid populations in each of the clinical samples
(Figure 6). Strikingly the ploidy of each of the four populations
was distinct. Two hypertetraploid populations were identified
in the primary tumor while the pleural effusion sample had a
hypodiploid and a hyperdiploid population. Each of these four
aneuploid populations was sorted and profiled for copy number
aberrations. The genomes of these four distinct populations had
shared as well as distinct aberrations that further define the clonal
heterogeneity of this tumor. For example the shared aberrations
included high level focal amplicons on chromosomes 3p and 10q.
We also detected aberrations that were present in one of the pri-
mary populations and in both of the populations detected in the
pleural effusion. This included an amplicon on chromosome Xp11
that includes the BMP15 locus (Figure 7A). The protein encoded
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FIGURE 5 | Clonal analysis of pancreatic ductal adenocarcinoma
(PDA) liver metastasis from SU2C clinical trial. (A) DNA content
flow sorting identified and purified a diploid and two distinct
aneuploid (2.7N, 3.2N) peaks in the single biopsy. (B) Whole
genome copy number profiles of the 2.7N and 3.2N populations. (C)
Aberration detection on chromosome 21 and (D) 21q12-q21.2 in
both aneuploid populations. Blue shaded areas denote ADM2
aberrant regions.
by this gene is a member of the bone morphogenetic protein family
which is part of the transforming growth factor-beta superfam-
ily. This protein is believed to be involved in oocyte maturation
and follicular development as a homodimer and by forming het-
erodimers with a related protein; Gdf9. In addition we detected a
homozygous deletion at 21q that simultaneously deleted the met-
allopeptidases ADAMTS1 and ADAMTS5 that was present only in
the pleural effusion populations (Figure 7B). The presence and
patterns of these amplicons and homozygous deletions in these
samples suggest that BMP15 amplification contributed to clonal
selection during progression, and that homozygous deletion of the
metallopeptidases contributed to the establishment of metastatic
lesions in this patient’s tumor.
However there were also aberrations that were present in the
primary populations but absent in the pleural effusion samples.
Specifically another focal amplicon on chromosome 6p target-
ing the progestin and adipoQ receptor family member VIII gene
locus (PAQR8; Figure 7C). The latter encodes a steroid mem-
brane receptor that binds progesterone and has been implicated
in normal oocyte maturation. The absence of this amplicon in
the pleural effusion samples suggests that the evolution of this
tumor may be driven by progenitor populations lacking the 6p
amplicon in a non-linear lineage. This relatively simple exam-
ple using single parameter sorting, aCGH, and two chronological
samples from a single patient highlight the potential complexity
of clonal evolution during tumor progression.
CLONAL HETEROGENEITY, EVOLUTION, AND ACQUIRED RESISTANCE
TO TARGETED THERAPY
The detection and sorting of more than one tumor population in
a biopsy and the availability of multiple biopsies from individual
patients extends the study of clinical phenotypes and the behaviors
of clonal populations in vivo. For example the aneuploid pop-
ulations with adverse histological features and multiple selected
genomic aberrations including a 5.7N population with high level
AR amplification that arose during the clinical history of a patient
who developed advanced PC, were uniquely sensitive to therapeu-
tic regimen and were erased after hormone withdrawal (Figure 8).
The patterns of acquired clonal aberrations, including losses on
chromosomes 1p, 1q, 12p, and 18q that persisted throughout
progression, suggest that the aneuploid populations arose from
diploid progenitors during the evolution of disease. Strikingly, the
co-occurring diploid cells acquired a low-level focal AR ampli-
con after bilateral orchiectomy leading to increased sensitivity to
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FIGURE 6 | Clonal analysis of matching metachronous primary
ovarian tumor and pleural effusion. (A) DNA content detection of
two distinct aneuploid populations in primary tumor samples from
2009. Whole genome copy number plots for each sorted population.
(B) DNA content detection of two distinct aneuploid populations in
pleural effusion tumor samples from 2010. Whole genome copy
number plots for each sorted population. Blue arrows shared
aberrations; red arrows pleural effusion specific aberrations; green
arrows primary specific aberrations; black arrows single primary and
shared pleural effusion aberrations.
FIGURE 7 | Genomic aberrations and clonal analysis of matching
metachronous primary ovarian tumor and pleural effusion. (A)
Chromosome X11p focal amplicon and BMP15. (B) Chromosome 21q21.3
homozygous deletion targeting ADAMTS1-ADAMTS5. (C) Chromosome
6p12.1-p12.3 amplicon and PAQR8. Blue shaded areas denote ADM2 defined
aberrant intervals.
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FIGURE 8 | Clonal analyses and evolution of androgen-independent
prostate carcinoma. Multiple populations were detected by DNA content
flow cytometry over an 8-year time span during the clinical history of a
prostate patient. Each population showed a series of shared (black) and novel
(red) genomic aberrations. (A) DNA content histograms and CGH summaries
for each biopsy. Diploid (2.0N) and aneuploid populations arose in 2000 and
evolved during clinical history of disease. (B) FISH analysis of chromosome X
(green centromere; red AR locus) and validation of AR amplicons arising in
2006. (C) PCR validation of homozygous deletion of FOXO3A gene in 2.0N
population that evolved after AR withdrawal therapy in 2008.
remaining levels of adrenal testosterone, followed by homozygous
deletion of FOXO3A in response to androgen blockage, resulting
in the evolution of androgen-independent metastatic disease. The
clonal relationships of these populations were further probed by
resequencing a panel of 400 cancer related genes, including the
AR gene, in the diploid and aneuploid populations from 2007 and
2008 biopsies. The AR gene was wild type in all three populations
and there were no somatic mutations that further distinguished
one population from the other. Thus our clonal analysis high-
lights the role of distinct but related tumor populations during the
evolution of resistant disease. The distinct AR amplicons present
in the diploid and the aneuploid populations that arose during
the evolution of androgen-independent metastatic PC, and the
homozygous deletion of the pro apoptotic FOXO3A gene would
have been obscured in a conventional histologically prepared sam-
ple. We propose that similar clonal behaviors of tumors, involving
target(s) asymmetrically distributed within a clonal lineage and
the selection for pro survival genomic aberrations underlie clin-
ical responses to existing and emerging targeted therapies. The
fundamental hypothesis is that clonal selection in the presence of
these agents will lead to rapid evolution and emergence of resistant
tumors. We are currently testing these hypotheses in a number of
tumor types.
CLONAL ANALYSIS: MULTI PARAMETER BASED FLOW SORTING
A limitation of single parameter DNA content sorting strategies is
the inability to resolve tumors that have a mean DNA content that
cannot be distinguished from normal diploid cells by flow cytom-
etry. One approach is to focus of the 4N peaks that may be present
in the population. Studies in Barrett’s esophagus, a known risk
factor for esophageal adenocarcinoma, have shown that 4N frac-
tions greater than 6% arise in neoplastic tissue and are associated
with known genomic events such as TP53 mutations (Galipeau
et al., 1996; Rabinovitch et al., 2001; Barrett et al., 2003). These
elevated 4N populations are frequently enriched with the G2/M
fractions of proliferating diploid cells as well as the G0/G1 frac-
tions of tetraploid populations. Alternatively DNA content can be
combined with a variety of markers to isolate populations based
www.frontiersin.org January 2013 | Volume 4 | Article 2 | 11
Barrett et al. Clonal evolution and solid tumors
on tissue type, differentiation, or proliferation status. For exam-
ple melan A combined with DNA content identified a diploid
melanocyte population in a lymph node metastasis sample whose
genome contained a series of aberrations including homozygous
deletion at 9p21.3 (Figure 9).
In addition to diploid tumor populations multiparameter sort-
ing resolves clonal heterogeneity in individual samples that would
otherwise be obscured by analysis of bulk samples. For example
whole exome analysis of single parameter DNA content sorted
2.0N and 3.0N populations from a PDA biopsy identified a series
of mutations and copy number aberrations in the aneuploid pop-
ulation (Figure 10). The total diploid sorted fraction from the
PDA tissues was non-aberrant by aCGH analysis. However a low
(<1–5%) number of reads for some mutations present in the ane-
uploid fraction (e.g., KRAS) were observed in the NGS data for
the total diploid fraction. The total diploid peaks in DNA con-
tent based flow sorted tumor samples may contain admixtures of
neoplastic and non-neoplastic cell types. To determine whether
these low frequency mutation reads are present in distinct sub-
populations of neoplastic cells we used a DAPI/cytokeratin 19 and
a DAPI/vimentin flow assay to resort the biopsy into four distinct
populations (Figure 10). The cytokeratin 19+ (CK19+) and the
vimentin+ (Vim+) diploid populations each had the heterozygous
KRAS mutation detected in the aneuploid population. However,
only the small (1–5%) CK 19+ diploid population had the clonal
homozygous TP53 mutation and an aCGH profile, including a
homozygous deletion of PARD3, which matched the 3.0N popu-
lation. Thus the 2N CK 19+ population represents a co-existing
diploid epithelial tumor population. In contrast the Vim+ diploid
KRASmut, TP53wt population was normal by aCGH and repre-
sents a third clonal population in this biopsy that is either from an
earlier stage of disease or is a non-progressing neoplastic popula-
tion. Our ability to resort this tissue provides a unique approach
to validate NGS results and confirm the presence of distinct clonal
populations. We propose that this iterative approach can be used
to exploit the detection of low frequency reads in NGS data of
clinical samples and to provide even deeper clonal analysis.
DISCUSSION AND CONCLUSION
DNA content based flow sorting of clinical samples provides highly
purified populations of tumor cells for genomic analyses. Conse-
quently the clonal behaviors of samples of interest, including the
presence of distinct populations of tumor cells and their differ-
ential responses to therapies, can be studied in patients in vivo.
We and others have shown that both tissue and clonal hetero-
geneity can vary widely even in adjacent biopsies from the same
tumor (Ruiz et al., 2011; Gerlinger et al., 2012). Gating based on
DNA content provides a highly reproducible quantitative mea-
sure for identifying and sorting tumor populations from samples
of interest. For example a 3.0N population sorted from a FF PDA
FIGURE 9 | Multiparemeter sorting and CGH analysis of melanoma
lymph node biopsy. (A) DNA content (x -axis) and melan A (y -axis) based
sorting identified a small melan A+ diploid fraction. (B) Whole genome view
of melan A− and melan A+ diploid genomes. (C) Chromosome 9 and
9p13.1-p24.1 views of homozygous deletion in diploid melan A+ genome.
Blue shaded area denotes ADM2 defined aberrant interval.
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FIGURE 10 | Clonal analysis of diploid and aneuploid populations in a
pancreatic ductal adenocarcinoma (PDA) biopsy. (A) DNA content
cytokeratin 19 multiparameter sort of PDA biopsy. A small (<5%) CK19+
fraction was detected and sorted from the biopsy. These were compared to
total 2.0N, 3.0N, and vimentin+ 2.0N populations sorted from the same
tissue. (B) Targeted resequencing of K-ras and TP53 in sorted CK19+ diploid,
sorted Vim+ diploid, and patient derived cell line. (C) Summary of clonal
content of PDA biopsy.
sample was detected 3 years later in an FFPE sample from the same
tissue (Holley et al., 2012). Genomic analysis including whole
exome sequencing, confirmed that the sorted 3.0N populations
were identical. The sorting efficiencies of clinical samples can be
significantly affected by the presence of debris, aggregates, and
sliced nuclei. To maintain sorting efficiencies at relatively high
levels (>80%) and high yields and purities of sorted samples
the differential pressure of the core and the sheath fluids can be
increased but cannot be ≥1. Slow sort rates while maintaining
optimal differential pressure of flow stream improves efficiency of
sorts and the overall yield of intact nuclei. However the greatest
variable in our sorting was the origin of the tissue. For exam-
ple triple negative breast cancer (TNBC) samples typically sort
more efficiently than PDA samples for both fresh frozen and FFPE
samples.
Our flow sorting based clonal genomic methods have been
designed to leverage highly valuable clinical samples. These meth-
ods aim to overcome some of the most common limitations to
the study of clinical samples including high admixtures of non-
neoplastic tissue, small sample size, and the presence of high levels
of necrosis. This extends the number of clinical samples that can be
interrogated allowing a more unbiased survey of each tumor type.
The most highly favorable samples for studying the clonal behav-
iors of tumors and their role in acquired resistance are clinical
biopsies obtained during clinical trials. The challenge for genomic
based investigations is to optimize the use of these increasingly
valuable samples and to profile each of them in an unbiased and
quantitative manner. Our ability to use FFPE tissues expands our
clonal analysis to this vast resource of clinically annotated samples
with patient follow-up data (Holley et al., 2012).
A fundamental hypothesis of our current studies is that the
presence and behaviors of distinct diploid and aneuploid popu-
lations in clinical samples whose genomes contain both shared
and unique will affect therapeutic responses and clinical out-
comes. This will be of increasing significance with the ongoing
development of more targeted therapies for human cancers. Cur-
rent NGS based studies use increasingly deep coverage and novel
algorithms to infer the presence of clonal populations in clinical
samples (Cancer Genome Atlas Research, 2011; Nik-Zainal et al.,
2012). In contrast our approach focuses on the identification and
purification of distinct populations of interest prior to genomic
analysis. Once identified these pure populations provide a clonal
framework to map the mutational and copy number landscape of
each tumors genome(s).
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Previous studies with sorted clinical samples have highlighted
the utility of purified sorted samples for epigenetic studies of
loci of interest (Wong et al., 1997). Currently we are using mul-
tiparameter sorting strategies in combination with high resolu-
tion NGS based methylation assays to investigate the epithelial
and mesenchymal components of tumors. We believe that this
level of investigation will further broaden the clinical applica-
tion of our clonal analysis methodology. Technological innova-
tions will also advance the use of increasingly smaller inputs
from sorted samples for deep genomic analyses. In particular
new sequencing platforms offer the potential for low inputs
which can remove the need for linear amplification of small
purified samples (Zong et al., 2012). The development of more
robust sequencing platforms and more efficient analysis pipelines
will eliminate the use of array based studies. Thus we antici-
pate for each sorted population isolated from clinical samples of
interest that a unified analysis of individual genomes, including
somatic mutations, structural variations, and copy number aber-
rations will be derived from a single experiment. We believe that
these analyses will provide an even deeper study of the clonal
landscape of each tumor that can be advanced for improved
patient care.
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